# Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE)

> **NCT02436668** · PHASE3 · COMPLETED · sponsor: **Pharmacyclics LLC.** · enrollment: 430 (actual)

## Conditions studied

- Metastatic Pancreatic Adenocarcinoma

## Interventions

- **DRUG:** Ibrutinib
- **DRUG:** Gemcitabine
- **DRUG:** Nab-paclitaxel

## Key facts

- **NCT ID:** NCT02436668
- **Lead sponsor:** Pharmacyclics LLC.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05
- **Primary completion:** 2018-10
- **Final completion:** 2019-04-25
- **Target enrollment:** 430 (ACTUAL)
- **Last updated:** 2020-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02436668

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02436668, "Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE)". Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/clinical/NCT02436668. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*